GUILD ASSOCIATES INC — Department of Defense SBIR Phase II: A17-131
GUILD ASSOCIATES INC — SBIR Phase II award from Department of Defense.
Phase II SBIR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- At $2,476,534, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Topic code A17-131 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $2,476,534
- Agency
- Department of Defense · Army
- Program / Phase
- SBIR · Phase II
- Topic
- A17-131
- Solicitation
- 17.2
- NAICS
- —
- Place of performance
- OH
- Period
- 2018-11-15 → 2023-10-02
Description
A rapid and accurate diagnosis of infectious diseases is essential to reducing lost duty days for U.S. Service Members and accurately tracking outbreaks. Patient samples frequently require cold storage during transport to a centralized diagnostic laboratory. During transport, antigens and antibodies may be degraded by proteases present in specimen samples and lead to a false-negative diagnosis of the patient. Point-of-care diagnostics are an inexpensive, easy and rapid diagnostic tool but many of these assays lack the sensitivity of sophisticated laboratory equipment. This Phase II SBIR proposal builds upon our successful Phase I effort where we demonstrated our SampleCAP technology can decrease sample volume, concentrate biomolecules and increase downstream assay sensitivity using forward osmosis. In this effort we will improve the prototype device design, performance, and usability following feedback from the DoD and diagnostic laboratories to meet the sensitivity and specificity requirements set forth by the DoD. SampleCAP’s ability to increase sensitivity will be demonstrated with clinical human samples and stability testing of packaged devices will be performed according to military standards. At the end of Phase II we will have optimized the device design and be prepared for transition to production and field testing of the device.